Telangiectasia, Hereditary Hemorrhagic Clinical Trial
Official title:
Investigation of Coagulation Parameters in Hereditary Haemorrhagic
We will address coagulation parameters in hereditary haemorrhagic telangiectasia (HHT) compared to controls.
The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable. We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state. We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03227263 -
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
|
Phase 3 | |
| Completed |
NCT00733655 -
Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Completed |
NCT00355108 -
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
|
Phase 3 | |
| Completed |
NCT01507480 -
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia
|
Phase 1 | |
| Completed |
NCT03910244 -
Pomalidomide for the Treatment of Bleeding in HHT
|
Phase 2 | |
| Completed |
NCT04108052 -
Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
|
N/A | |
| Recruiting |
NCT04976036 -
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
|
Phase 2 | |
| Completed |
NCT00684879 -
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
|
||
| Completed |
NCT00004648 -
Studies of Hereditary Hemorrhagic Telangiectasia
|
N/A | |
| Completed |
NCT00230672 -
Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
|
||
| Completed |
NCT03954782 -
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
|
Phase 2 | |
| Completed |
NCT02484716 -
Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)
|
Phase 2 | |
| Recruiting |
NCT00230685 -
Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Terminated |
NCT02204371 -
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
|
Phase 2 | |
| Recruiting |
NCT00230620 -
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
|
||
| Recruiting |
NCT02157987 -
Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
|
Phase 1/Phase 2 | |
| Completed |
NCT01408030 -
North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Withdrawn |
NCT00733629 -
Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Active, not recruiting |
NCT00230633 -
Studies of White Blood Cells Derived From HHT Patients
|
||
| Recruiting |
NCT05933330 -
Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database
|